TBPH
Theravance Biopharma, Inc.NASDAQHealthcare$16.02+0.50%ClosedMarket Cap: $824.9M
As of 2026-04-06
Valuation
P/E (TTM)
7.79
PEG
0.03
P/B
2.76
P/S
7.71
EV/EBITDA
890.84
DCF Value
$-104.65
FCF Yield
28.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
94.9%
Operating Margin
-12.3%
Net Margin
98.5%
ROE
46.0%
ROA
21.8%
ROIC
-2.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $45.9M | 153.5% | $10.4M | $61.0M | $1.15 | — |
| FY 2025 | $107.5M | 94.9% | $-13.2M | $105.9M | $2.06 | — |
| Q3 2025 | $20.0M | 59.4% | $-6.5M | $3.6M | $0.07 | — |
| Q2 2025 | $26.2M | 60.0% | $-2.7M | $54.8M | $1.08 | — |
| Q1 2025 | $15.4M | 25.6% | $-14.4M | $-13.6M | $-0.27 | — |
| Q4 2024 | $18.8M | 100.0% | $-9.2M | $-15.5M | $-0.31 | — |
| FY 2024 | $64.4M | 100.0% | $-46.9M | $-56.4M | $-1.15 | — |
| Q3 2024 | $16.9M | 45.1% | $-10.8M | $-12.7M | $-0.26 | — |
| Q2 2024 | $14.3M | 30.2% | $-15.7M | $-16.5M | $-0.34 | — |
| Q1 2024 | $14.5M | 38.2% | $-11.2M | $-11.7M | $-0.24 | — |
| Q4 2023 | $17.6M | 52.7% | $-6.2M | $-8.5M | $-0.17 | — |
| FY 2023 | $57.4M | 29.3% | $-56.0M | $-55.2M | $-1.00 | — |